Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Schering-Plough 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Schering-Plough 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough

2Q Revenues: $3.2 billion (+13%)

2Q Earnings: $539 million (+108%)

YTD Revenues: $6.2 billion (+15%)

YTD Earnings: $1.1 billion (+75%)

Comments: SP’s Remicade sales were up 28% to $394 million. Nasonex sales grew 22% to $295 million. Combined Vytorin/Zetia sales were $1.3 billion (shared with Merck). R&D expenses rose $160 million to $696 million, including a $60 million upfront payment for a licensing deal with Novacea.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters